|
Hokkaido University Collection of Scholarly and Academic Papers >
International Institute for Zoonosis Control >
Peer-reviewed Journal Articles, etc >
A Pilot Study on Developing Mucosal Vaccine against Alveolar Echinococcosis (AE) Using Recombinant Tetraspanin 3 : Vaccine Efficacy and Immunology
This item is licensed under:Creative Commons Attribution 3.0 Unported
| Title: | A Pilot Study on Developing Mucosal Vaccine against Alveolar Echinococcosis (AE) Using Recombinant Tetraspanin 3 : Vaccine Efficacy and Immunology |
| Authors: | Dang, Zhisheng Browse this author | | Yagi, Kinpei Browse this author | | Oku, Yuzaburo Browse this author →KAKEN DB | | Kouguchi, Hirokazu Browse this author →KAKEN DB | | Kajino, Kiichi Browse this author →KAKEN DB | | Matsumoto, Jun Browse this author | | Nakao, Ryo Browse this author →KAKEN DB | | Wakaguri, Hiroyuki Browse this author | | Toyoda, Atsushi Browse this author | | Yin, Hong Browse this author | | Sugimoto, Chihiro Browse this author →KAKEN DB |
| Issue Date: | 27-Mar-2012 |
| Publisher: | Public Library of Science |
| Journal Title: | PLoS Neglected Tropical Diseases |
| Volume: | 6 |
| Issue: | 3 |
| Start Page: | e1570 |
| Publisher DOI: | 10.1371/journal.pntd.0001570 |
| Abstract: | Background: We have previously evaluated the vaccine efficacies of seven tetraspanins of Echinococcus multilocularis (Em-TSP1-7) against alveolar echinococcosis (AE) by subcutaneous (s.c.) administration with Freund's adjuvant. Over 85% of liver cyst lesion number reductions (CLNR) were achieved by recombinant Em-TSP1 (rEm-TSP1) and -TSP3 (rEm-TSP3). However, to develop an efficient and safe human vaccine, the efficacy of TSP mucosal vaccines must be thoroughly evaluated. Methodology/Principal Findings: rEm-TSP1 and -TSP3 along with nontoxic CpG ODN (CpG oligodeoxynucleotides) adjuvant were intranasally (i.n.) immunized to BALB/c mice and their vaccine efficacies were evaluated by counting liver CLNR (experiment I). 37.1% (p<0.05) and 62.1% (p<0.001) of CLNR were achieved by these two proteins, respectively. To study the protection-associated immune responses induced by rEm-TSP3 via different immunization routes (i.n. administration with CpG or s. c. immunization with Freund's adjuvant), the systemic and mucosal antibody responses were detected by ELISA (experiment II). S. c. and i.n. administration of rEm-TSP3 achieved 81.9% (p<0.001) and 62.8% (p<0.01) CLNR in the liver, respectively. Both the immunization routes evoked strong serum IgG, IgG1 and IgG2a responses; i.n. immunization induced significantly higher IgA responses in nasal cavity and intestine compared with s. c. immunization (p<0.001). Both immunization routes induced extremely strong liver IgA antibody responses (p<0.001). The Th1 and Th2 cell responses were assessed by examining the IgG1/IgG2 alpha ratio at two and three weeks post-immunization. S. c. immunization resulted in a reduction in the IgG1/IgG2 alpha ratio (Th1 tendency), whereas i.n. immunization caused a shift from Th1 to Th2. Moreover, immunohistochemistry showed that Em-TSP1 and -TSP3 were extensively located on the surface of E. multilocularis cysts, protoscoleces and adult worms with additional expression of Em-TSP3 in the inner part of protoscoleces and oncospheres. Conclusions: Our study indicated that i.n. administration of rEm-TSP3 with CpG is able to induce both systemic and local immune responses and thus provides significant protection against AE. |
| Rights: | http://creativecommons.org/licenses/by/3.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/49119 |
| Appears in Collections: | 人獣共通感染症国際共同研究所 (International Institute for Zoonosis Control) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 杉本 千尋
|
